SCHEMBL5536216

SCHEMBL5536216

[CH2]CCC(=O)N1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
SMN1; SMN2 Q16637 7/20 0.58
NPC1 O15118 7/20 0.58
RAB9A P51151 6/20 0.58
CYP2C19 P33261 1/20 0.56
MAPT P10636 2/20 0.50
GAA P10253 1/20 0.50
ALDH1A1 P00352 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
DPP4 P27487 1/20 0.47
F13A1 P00488 1/20 0.47
TGM2 P21980 1/20 0.47
TGM1 P22735 1/20 0.47
GRIN2B Q13224 2/20 0.47
HTT P42858 1/20 0.47
GRM5 P41594 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537274 0.92 L3MBTL1 (0.58) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL5540430 0.89 L3MBTL1 (0.55) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL6388570 0.88 MEN1 (0.62) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL23693070 0.87 L3MBTL1 (0.62) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL13548728 0.87 L3MBTL1 (0.79) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL7393652 0.86 MEN1 (0.76) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL3970912 0.86 MEN1 (0.76) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL4814264 0.86 MEN1 (0.76) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL379160 0.86 MEN1 (0.76) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
Bicarbonate SCHEMBL4357688 0.85 MEN1 (0.73) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.